Safety Study of PLX4032 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this FIH study is to assess the safety and pharmacokinetics of
PLX4032 in patients with solid tumors. The secondary objective is to assess the
pharmacodynamic activity in paired biopsy specimens obtained from patients with malignant
melanoma who have the V600E BRAF oncogenic mutation.